Case Name: CLASSEN IMMUNOTHERAPIES, INC., Plaintiff-Appellant, v. BIOGEN IDEC, Defendant-Appellee, and GlaxoSmithKline, Defendant-Appellee, and Merck & Co., Inc., Defendant-Appellee, and Kaiser Foundation Health Plan, Inc., Defendant-Appellee
Court: United States Court of Appeals for the Federal Circuit
Jurisdiction: United States
Decision Date: 2006-04-10
Citations: 178 F. App'x 14
Docket Number: No. 2006-1216
Parties: CLASSEN IMMUNOTHERAPIES, INC., Plaintiff-Appellant, v. BIOGEN IDEC, Defendant-Appellee, and GlaxoSmithKline, Defendant-Appellee, and Merck & Co., Inc., Defendant-Appellee, and Kaiser Foundation Health Plan, Inc., Defendant-Appellee.
Judges: Before MICHEL, Chief Judge, GAJARSA and PROST, Circuit Judges.
Reporter: West's Federal Appendix
Volume: 178
Pages: 14–14

Head Matter:
CLASSEN IMMUNOTHERAPIES, INC., Plaintiff-Appellant, v. BIOGEN IDEC, Defendant-Appellee, and GlaxoSmithKline, Defendant-Appellee, and Merck & Co., Inc., Defendant-Appellee, and Kaiser Foundation Health Plan, Inc., Defendant-Appellee.
No. 2006-1216.
United States Court of Appeals, Federal Circuit.
April 10, 2006.
Before MICHEL, Chief Judge, GAJARSA and PROST, Circuit Judges.

Opinion:
ON MOTION
MICHEL, Chief Judge.
ORDER
GlaxoSmithKline (GSK) moves to dismiss this appeal, from the United States District Court for the District of Maryland in 04-CV-02607, for lack of jurisdiction. GSK also moves for fees and costs. Clas-sen Immunotherapies, Inc. submits an opposition, out of time. GSK replies.
Classen sued the defendants for infringement. The district court granted motions to dismiss certain counts of Clas-sen's complaint and granted Merck & Co., Inc.'s motion for summary judgment of noninfringement. However, Merck's counterclaim for a declaratory judgment of invalidity remains pending and, indeed, a trial date has been set. Thus, there is no final judgment and any appeal is premature. Nystrom v. TREX Co., Inc., 339 F.3d 1347 (Fed.Cir.2003).
Accordingly,
IT IS ORDERED THAT:
(1) The motion to dismiss is granted.
(2) The motion for fees is denied.
(3) Costs awarded to GSK.